Method Validation for the Quantification of Mitragynine in Blood and Urine by Using Online Solid Phase Extraction Liquid Chromatography-Mass Spectrometry

Main Article Content

Phatraporn Chodchoy

Abstract

Kratom (Mitragyna speciosa Korth) is a tropical plant in Thailand, which an addictive effect. Kratom is classified as a Penal Drug Category-5 of the Thai Narcotics Act 2522 (1979), the least restrictive and punitive level. Mitragynine is a major alkaloid of Kratom and is responsible for its opioid effects, which has pharmacological action. Therefore may increase the use of kratom by pretending to be medical benefits. This research aims to study method validation to quantify Mitragynine from Kratom in serum and urine by using Online-SPE-LC-MS/MS. This method has six topics for validation. First, the linearity has r2 (0.995 - 1.000) in blood and urine equal to 0.9998 and 0.9992, respectively. Second, the specificity has not to be disturbed in the chromatogram of Mitragynine in the blood and urine. Third, the accuracy with %recovery (± 15%) in blood and urine equal to 95.25-109.12% and 94.98-111.20%, respectively. Forth, the precision shows that the Intraday-Precision and Interday-Precision values ​​are %RSD (<15%) within acceptable levels in both blood and urine. Fifth, the detection limit (S/N ratio > 3) in the blood and urine is equal to 0.20, 0.15 ng/mL, respectively. And sixth, the limit of quantitation (S/N ratio > 10) in the blood and urine is equal to 1.0, 2.0 ng/mL, respectively. The obtained LOQ has to be in the right criteria. The determination of Mitragynine in the blood and urine using this method is appropriate. This method could analyze samples precisely and reliably.

Article Details

How to Cite
1.
Chodchoy P. Method Validation for the Quantification of Mitragynine in Blood and Urine by Using Online Solid Phase Extraction Liquid Chromatography-Mass Spectrometry. J Appl Res Sci Tech [Internet]. 2021 Oct. 18 [cited 2024 Jun. 16];20(2):88-101. Available from: https://ph01.tci-thaijo.org/index.php/rmutt-journal/article/view/241642
Section
Research Articles

References

Narcotics Act (No. 7) B.E. 2562 (2019). Government Gazette Volume 136, Part 19 (dated 18 February 2019).

Kratom (Mitragyna speciosa) drug profile [Internet]. Portugal: The European Monitoring Centre for Drugs and Drug Addiction. [cited 2021 Jul 2]. Available from: https://www.emcdda.europa.eu/publications/drug-profiles/kratom.

Ya K, Tangamornsuksan W, Scholfield CN, Methaneethorn J, Lohitnavy M. Pharmacokinetics of mitragynine, a major analgesic alkaloid in kratom (Mitragyna speciosa): A systematic review. Asian J Psychiatr. 2019;43:73–82.

Suhaimi FW, Yusoff NHM, Hassan R, Mansor SM, Navaratnam V, Müller CP, et al. Neurobiology of Kratom and its main alkaloid mitragynine. Brain Res Bull. 2016;126(Pt 1):29–40.

Kamble SH, Sharma A, King TI, León F, McCurdy CR, Avery BA. Metabolite profiling and identification of enzymes responsible for the metabolism of mitragynine, the major alkaloid of Mitragyna speciosa (kratom). Xenobiotica. 2019;49(11):1279–88.

Churaithip Wangsinthaveeku. Kratom (Kratom) [Internet]. 2017 [accessed 25 Nov. 2019]. Accessed from: http://ccpe.pharmacycouncil.org.

Meireles V, Rosado T, Barroso M, Soares S, Gonçalves J, Luís Â, et al. Mitragyna speciosa: Clinical, Toxicological Aspects and Analysis in Biological and Non-Biological Samples. Med (Basel, Switzerland). 2019;6(1):35.

Guidance for industry-Bioanalytical method validation [Internet]. United States: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine. 2018 [cited 2019 Nov 10]. Available from: https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf